Search results
Results from the WOW.Com Content Network
The presence of KRAS mutations in colorectal cancer tissue indicates that the patient may not benefit from treatment with Erbitux. If the test result indicates that the KRAS mutations are absent in the colorectal cancer cells, then the patient may be considered for treatment with Erbitux. [41]
Sotorasib, sold under the brand names Lumakras and Lumykras, is an anti-cancer medication used to treat non-small-cell lung cancer. [4] [5] It targets a specific mutation, G12C, in the protein K-Ras encoded by gene KRAS which is responsible for various forms of cancer. [7] [8] Sotorasib is an inhibitor of the RAS GTPase family. [4]
mRNA-5671 also known as V941 is a cancer vaccine candidate developed by Moderna. [1] It is a tetravalent vaccine that targets G12D, G12V, G13D or G12C driver mutations in the KRAS gene. [ 2 ] It is currently being evaluated for the treatment of either non-small cell lung cancer , colorectal cancers with microsatellite instability , or ...
The treatment of colorectal cancer can be aimed at cure or palliation. The decision on which aim to adopt depends on various factors, including the person's health and preferences, as well as the stage of the tumor. [139] Assessment in multidisciplinary teams is a critical part of determining whether the patient is suitable for surgery or not ...
Over a 45-years span — between 1975 and 2020 — improvements in cancer screenings and prevention strategies have reduced deaths from five common cancers more than any advances in treatments ...
While numerous challenges exist in translating biomarker research into the clinical space; a number of gene and protein based biomarkers have already been used at some point in patient care; including, AFP (liver cancer), BCR-ABL (chronic myeloid leukemia), BRCA1 / BRCA2 (breast/ovarian cancer), BRAF V600E (melanoma/colorectal cancer), CA-125 ...
A new study found higher levels of inflammation in colorectal cancer tumors, suppressing the body’s ability to fight the disease.. Researchers note the typical Western diet is a driver of ...
Selumetinib, had a phase 2 clinical trial for non-small cell lung cancer (NSCLC) which demonstrated an improvement in PFS, [5] and is now in phase III development in KRAS mutation positive NSCLC (SELECT-1, NCT01933932). Other ph 3 clinical trials underway include uveal melanoma (failed), and differentiated thyroid carcinoma.